The US Food and Drug Administration (FDA) has just approved a new drug called Tavalisse™ to treat adults who have thrombocytopenia as a result of chronic immune thrombocytopenia (ITP), following the failure of a previous treatment.
To read the full press release including a video from the developers, Rigel Pharmaceuticals, click here.